Purpose: To compare outcomes of patients treated for pararenal aortic aneurysms using fenestrated endovascular aneurysm repair (fEVAR) vs open surgical repair (OSR) in 3 high-volume centers. Materials and Methods: A multicenter retrospective analysis was conducted of 200 pararenal abdominal aortic aneurysm patients electively treated with OSR (n=108) or fEVAR (n=92) from 1998 to 2015 at 3 tertiary institutions. Endpoints were 30-day morbidity and mortality, late reinterventions, visceral artery occlusion, and mortality. Analysis was conducted on the entire population and on a propensity score-matched population constructed on age, gender, coronary artery disease (CAD), and chronic renal failure. Results: In the total cohort, fEVAR patients were significantly (p<0.001) older and had higher frequencies of CAD (p<0.001) and previous stroke (p=0.003). OSR patients had higher risk of perioperative morbidity (OR 2.5, 95% CI 1.09 to 5.71, p=0.033), specifically respiratory failure (OR 4.06, 95% CI 1.12 to 4.72, p=0.034). These findings were confirmed in the propensity-adjusted analysis, where cardiac complications were also higher after OSR (OR 12.8, 95% CI 0.07 to 0.21, p=0.02). No difference in perioperative mortality (2.2% in fEVAR vs 1.9% in OSR) was identified. Mean follow-up was 50 months (range 0-119). Four-year results showed higher survival (91.2% vs 69.3%, p=0.02) and freedom from reintervention (95.6% vs 77.8%, p=0.01) after OSR in the unmatched population, with a small but significant (p=0.021) difference in the risk of late visceral artery occlusion/stenosis after fEVAR. On propensity analysis, no differences in late survival were found between groups. Conclusion: fEVAR and OSR may afford similar early and midterm survival rates. Higher risks of perioperative systemic complications after OSR are counterbalanced by higher risks of late visceral vessel patency issues and need for reintervention after fEVAR. Both procedures are safe and effective in the long term in experienced centers, where patient evaluation should drive the treatment strategy.
Introduction
Pararenal aortic aneurysms are complex lesions whose preferred treatment is still debated. Open surgical repair (OSR) is technically demanding, requiring wide exposure of the aorta and a high clamping level (inter-renal, suprarenal, supramesenteric, or supraceliac), and is associated with a higher risk of postoperative morbidity and mortality compared with surgical treatment of infrarenal aneurysms. 1, 2 On the other hand, the growing expertise in endovascular repairs has led interventionists to treat more complex aortic anatomies. To incorporate the visceral vessels into the repair and extend the proximal sealing zone, fenestrated endovascular aortic repair (fEVAR) emerged and has gained acceptance in centers of excellence.
The aim of the present study was to compare short-and midterm outcomes of patients treated with fEVAR and OSR for pararenal aortic aneurysms in patients from a group of highvolume centers in which both techniques were sufficiently well established to allow an up-to-date comparison of results.
Materials and Methods

Study Design
Vascular databases containing prospectively collected data on consecutive patients electively treated with OSR (January 1998 to May 2016) or fEVAR (January 2006 to December 2015) at 3 tertiary institutions were merged for this analysis. All centers involved had long experiences with both surgical and endovascular repairs of complex aortic pathologies. Patients requiring urgent or emergent treatment for symptomatic or ruptured aneurysms were excluded from this analysis. All efforts were made to obtain complete follow-up information on the study patients. Missing data for those with an overdue follow-up >18 months were obtained when feasible through telephone interviews with patients, family, or general practitioners. Patient consent forms signed at the time of the procedure at all facilities included consent for the use of anonymized data for scientific purposes. The ethics committees of all centers waived the need for approval of the retrospective analysis.
Patient Population
Of the 200 patients available for this analysis, 92 (46%) patients (mean age 74.9±6.5 years; 3 men) were treated with fEVAR and 108 (54%) patients (mean age 70.6±7 years; 102 men) were treated with open surgery. Table 1 compares the baseline variables of the subgroups. The fEVAR and the OSR groups differed in age, coronary artery disease (CAD), and history of stroke (Table 1) . The OSR patients more frequently had chronic renal failure (not dialysis-dependent in all cases). A propensity-matched cohort was selected for analysis based on age, gender, CAD, and renal failure, which was defined as a creatinine level ≥1.5 mg/dL.
Procedures
In the 108-patient OSR group, suprarenal clamping was the most commonly used (62% of total). An aorto-aortic reconstruction was chosen in 56 (51.9%) patients, while an aortobi-iliac bypass was preferred in 37 (34.3%) cases. An aortobifemoral bypass was performed in 3 (2.8%) patients. In 12 cases, the type of reconstruction was not detailed. Reconstruction of a renal artery was performed in 3 cases (reimplantation in 2 and aortorenal bypass in 1). The mean visceral clamping time was 30±21 minutes.
In the 92-patient fEVAR group, all patients were treated with the Zenith fenestrated stent-graft (Cook Medical, Bloomington, IN, USA). One visceral vessel was targeted in 8 (8.7%) cases, 2 visceral vessels in 30 (32.6%), 3 vessels in 29 (31.5%), and 4 vessels in 25 (27.2%) patients. Surgical cutdown was used in the majority of procedures (n=78); in one of these an iliac conduit was employed as a main access. Bilateral percutaneous access was used in 13 cases, and a percutaneous and a surgical access were needed in the 
Definitions and Outcomes
Major adverse events (MAEs) included clinically relevant conditions occurring <30 days after the procedure, such as any cardiac complications (heart failure, myocardial infarction, arrhythmias); pulmonary complications (pneumonia, respiratory failure); and renal complications (acute renal failure and kidney infarction). Gastrointestinal complications included acute pancreatitis and necrotic cholecystitis. Neurological complications were also considered in this analysis, including perioperative strokes, transient ischemic attacks (TIAs), and paraplegia. Graft-related complications included severe graft kinks (diagnosed at duplex scan or computed tomography angiography); bleedings related to the graft; and graft or stent-graft occlusions. Access-related complications included wound dehiscence, bleeding, and occlusions at the level of the access vessels. Primary endpoints of the study were perioperative mortality and morbidity and death from any cause and aneurysm-related death in follow-up. Secondary endpoints were early and late reinterventions and visceral artery occlusions.
Statistical Analysis
Categorical variables are expressed as numbers and percentages; continuous variables are given as the mean ± standard deviation. Dichotomous variables were evaluated using chi-squared analysis. Categorical and continuous variables were compared with a t test. A propensity score according to type of treatment was constructed from a binary logistic regression using age, gender, CAD, and renal failure with a matching method that selected more than one participant from the OSR group for every patient in the fEVAR group.
Multivariate analyses (backward stepwise method) were used to identify the independent predictors of each of the outcomes in the entire cohort and in the propensity-matched cohorts. For the early death (<30 days) outcome, a multivariate binary logistic regression model was built using preoperative CAD, chronic obstructive pulmonary disease, procedure duration, access-related complications, and any systemic complication as covariates based on outcomes of bivariate analysis. Also the type of treatment was added to the analysis. A second multivariate binary logistic model was built for early systemic complications using CAD, chronic obstructive pulmonary disease, procedure duration, and type of treatment as covariates. The results of comparative analyses are reported as the odds ratio (OR) and 95% confidence interval (CI). Survival analysis was performed with Kaplan-Meier methods, using the log-rank test when applicable. A p value <0.05 was considered significant in all tests. Analysis was performed using SPSS Statistics for Windows (version 22.0, IBM Corporation, Armonk, NY, USA).
Results
Immediate and 30-Day Outcomes
Total operation time did not differ significantly between the 2 types of treatment (218±98 minutes for OSR vs 237±103 minutes for fEVAR, p=0.216), while estimated blood loss was significantly higher in the OSR group (758±839 vs 344±72 mL for fEVAR, p=0.001). Mean in-hospital stay was 10.4±13 days, with no significant difference between the 2 groups (p=0.15).
Complications. Overall, 32 (16%) patients reported a systemic complication (Table 2) , with OSR patients more likely to experience MAEs (21.3% vs 9.8% in fEVAR; OR 2.5, 95% CI 1.09 to 5.71, p=0.033). The overall rate of cardiac complications was 9.5%, with a higher rate in OSR patients (13% vs 5.4% in fEVAR, p=0.09). The rate of respiratory complications was significantly higher in the OSR group (12% vs 3.3%; OR 4.06, 95% CI 1.12 to 4.72, p=0.034). Patients undergoing fEVAR were at higher risk for access-related complications, such as bleeding or occlusions of the access vessels (OR 10.1, 95% CI 0.01 to 0.83, p=0.013). Perioperative acute renal failure occurred at similar rates in fEVAR and OSR patients [4 (4.3%) vs 5 (5.6%), p>0.99]. No difference was found between the groups in the rates of early and graft-related complications requiring reinterventions. There were 6 cases of limb ischemia (2 OSR and 4 fEVAR) and 2 visceral artery occlusions (both fEVAR). None of the baseline characteristics (age, gender, or comorbidities) affected systemic complications.
Similarly, in the propensity score-matched cohorts (41 fEVAR vs 102 OSR), the OSR patients were more likely to sustain a systemic complication (OR 11, 95% CI 0.01 to 0.85, p=0.005). In particular, respiratory (OR 12.8, 95% CI 0.07 to 0.21, p=0.02) and cardiac complications (OR 12.8, 95% CI 0.07 to 0.21, p=0.02) were higher in this group. The rates of perioperative acute renal failure were similar in fEVAR and OSR patients also in the matched population. Access-related complications were more frequent in the endovascular group (OR 10.1, 95% CI 0.012 to 1.009; p=0.024) as for the unmatched comparison.
The multivariate binary logistic model for early systemic complications explained 20.8% of the variation (Nagelkerke R 2 ) and correctly classified 83% of patients. Total operation time (OR 1.008, 95% CI 1.003 to 1.013, p=0.002) and open treatment (OR 5.18, 95% CI 1.84 to 14.6, p=0.002) were independent predictors of any systemic complication. Applying the same model to the matched cohort confirmed the type of treatment as the only independent predictor of early systemic complications (OR 18, 95% CI 2 to 158, p=0.009).
Death. At 30 days, overall mortality was 2%: 2.2% (n=2) in the fEVAR group vs 1.9% (n=2) in OSR. In-hospital death was associated with access site complications (p=0.025), perioperative sepsis (p=0.04), and duration of procedure (p=0.019). No baseline characteristics or other perioperative complications significantly affected early survival.
In the multivariate analysis for early death (<30 days), the model explained 51.4% of the variation (Nagelkerke R 2 ) and correctly classified 98.2% of patients. Only accessrelated complications were an independent predictor of early death (OR 27; 95% CI 3.3 to 220, p=0.002); type of treatment was not associated with early death at multivariate analysis.
Midterm Results
Mean follow-up was 50 months (range 0-119). Eleven patients were lost to follow-up (5 in the OSR group and 6 in the fEVAR group). Patients in the OSR group had a significantly longer follow-up in comparison with fEVAR patients (57±50 vs 26±24 months, respectively).
Including the 4 perioperative deaths, 33 (16.5%) patients died. The causes of the 29 deaths (12 fEVAR and 17 OSR) are summarized in Table 3 . No aneurysm-related deaths were recorded. Estimated survival for the total population ( Figure 1A ) was 69.3% and 91.2% in the fEVAR and OSR groups, respectively, at 48 months (p=0.02). Freedom from reintervention ( Figure 1B ) at 48 months was significantly higher in the OSR group compared with the endovascular group (95.6% vs 77.8%, p=0.01). Causes of late reintervention are listed in Table 3 . At the last follow-up in the endovascular group, 12 patients had endoleak (10 type II, 1 type III, and 1 types Ia and III). The patient with 2 endoleaks died 5 months after the procedure from acute myocardial infarction before receiving endoleak treatment. The individual type III endoleak was due to failed intraprocedural stenting of a renal artery. The patient underwent regular clinical and radiological follow-up, refusing reintervention, and showed sac shrinkage due to graft sealing at the distal portion of the neck, where an aortic stricture was present. Among the type II endoleaks, reintervention (coil embolization of the inferior mesenteric artery) was required in only 1 patient with sac enlargement.
Late visceral artery occlusion or stenosis occurred in 3 (1.5%) patients without significant difference in the OSR vs fEVAR groups [1 (0.9%) vs 2 (2.2%), respectively; p=0.6]. Renal stent compression occurred in 1 patient; the resulting stenosis was left untreated. In the OSR group, 1 late renal artery stenosis occurred in a patient without renal artery bypass or reimplantation; the lesion was successfully treated with renal stenting. In the fEVAR group, a renal artery occlusion and a superior mesenteric artery stenosis occurred. In the former no reintervention was performed since the patient was referred to the hospital >1 week after the onset of symptoms (flank pain). The stenosis was successfully treated with stenting. Freedom from late visceral stenosis or occlusion was significantly higher in the OSR group (p=0.021; Figure 1C) .
To correct for factors that potentially could affect late survival, the analysis was applied to the propensity-matched cohort, which had a mean follow-up of 48 months (range 0-196), significantly longer for the OSR group (54±48 in OSR vs 32±28 in fEVAR, p=0.009). Kaplan-Meier estimates of survival in the matched cohort ( Figure 1D) showed comparable survival at 36 months (p=0.67).
Discussion
The utility of fEVAR as the better treatment strategy for eligible patients with juxta-and pararenal aneurysms has not been established. The minimally invasive endovascular solution appears to be more attractive to patients at high risk for open surgery, but limited data have been collected regarding comparative results in those fit for both types of repair. Reaching level-1 evidence in this field seems beyond realistic expectations in the years to come. Given the experience needed for complex aortic repairs with fEVAR, it will take time to reach the same level of expertise already achieved with open surgery in most vascular units. In this light, the present study provides comparative midterm results in similar populations of patients treated in centers with mature experience in both open and endovascular surgery.
Current literature has addressed mostly the short-term outcomes of fEVAR compared to open repair, demonstrating similar early mortality and morbidity in concurrent populations of patients generally not comparable in terms of preoperative risks. Canavati et al 6 reported a single-center experience of 107 patients with pararenal aortic aneurysms treated either with open or endovascular repair. Their comparison revealed a lower rate of perioperative major complications, decreased intensive care unit utilization, and shorter in-hospital postoperative stay in the fEVAR group with similar early mortality, as in our study. These findings were supported by a large literature review, 7 which found identical perioperative death rates between the 2 treatments but more perioperative systemic complications in the open group.
Conversely, in a concurrent study from Raux et al, 8 the mortality risk of fEVAR patients was reported as high as 9.5%, 5 times higher than that of the OSR group. The authors underlined that most of the early deaths (3 of 4) were due to mesenteric infarction secondary to cholesterol embolization. This complication was not observed in our study, possibly because different selection criteria were adopted for patients undergoing endovascular treatment. In our centers, patients with a shaggy aorta or with free floating thrombus are usually excluded from fEVAR based on considerable previous experience with endovascular aortic repairs.
Other comparative studies have focused on the 2 alternatives without providing valid results, mostly owing to selection bias. In the widest study available, Orr et al 9 reviewed the results of open (n=610) vs endovascular (n=395) repair of 1005 juxta-and pararenal aneurysms from the National Surgical Quality Improvement Program database. They derived 2 propensity-matched groups of 263 patients each from among 789 juxtarenal and 216 pararenal aneurysms. Unfortunately, in the endovascular group, the authors included simple EVAR together with fEVAR and chimney EVAR, generating confusion both for inclusion criteria (patients with short infrarenal neck suitable for standard EVAR) and for technical differences (chimneys vs fenestrations). However, again the results of EVAR and OSR were similar in terms of early mortality, with a benefit for endovascular treatment regarding perioperative morbidity, as others have reported. 10 In our study, all fenestrated endovascular repairs were accomplished with a single model of endograft, therefore providing a homogeneous technique. The endovascular patients were significantly older and more frequently affected by CAD and stroke, but OSR patients had a higher rate of chronic renal failure, though this association did not reach statistical significance. This reflects the general preference of open repair for patients with renal insufficiency to avoid the administration of contrast both intraoperatively and during follow-up, though recent studies have attested to the safety of endovascular aortic procedures on perioperative renal outcome and midterm results that challenge OSR. 11, 12 Perioperative findings in our study confirm most of the known early benefits of endovascular treatment compared with open surgery, both for AAA and for more proximal aortic diseases. In particular, in the present study, fEVAR was shown to reduce systemic complications, mostly due to reduction in respiratory complications, as already shown after EVAR for AAA. 13, 14 Previous comparative studies on open vs endovascular treatment of thoracoabdominal aneurysms found similar reductions in respiratory complications influencing the perioperative results. 15 In our experience, midterm survival of fEVAR patients was obviously worse than that of the OSR patients due to differences in age and other clinical risk factors. However, use of propensity-matched groups allowed evaluation of early and late results in the 2 surgical options. Interestingly, survival rates were similar for the groups at both 30 days and 3 years, with a low rate of late death (18%) and absence of aneurysm-related deaths. These figures clearly demonstrate that fEVAR is still the preferred option for high-risk patients, while OSR is offered to standard risk patients. However, results were promising in the subgroup of propensity-adjusted fEVAR patients, rendering the minimally invasive alternative appealing for at least some standard risk subjects.
During follow-up in our endovascular population, a higher risk of reintervention was demonstrated in comparison to the OSR patients. The need for secondary intervention was similar to that reported in the review article by Rao et al, 7 where risk of reintervention was 4.9% for OSR vs 12.7% for fEVAR (OR 0.334, 95% CI 0.212 to 0.525, p<0.001). This risk of late failures of fEVAR requiring reintervention should be taken into account when the choice has to be made between the treatment options in subjects suitable for both: Young patients may indeed prefer a more invasive but more durable repair.
Limitations
Our study presents multiple limitations. The database used and the analysis did not take into consideration those patients who were refused an intervention. Propensity analysis did not allow a totally balanced comparison and resulted in a small subset of comparable patients. These numbers decreased the power in detecting differences in treatment efficacy, as in other studies on the same subject. The present finding of similar survival after both treatment options should not prompt the conclusion that they are indeed similar and can be offered randomly to a single patient. The choice should be individualized to obtain the best results in different patients.
The limitation due to the retrospective nature of the study has been only in part attenuated by the prospective collection of the data in the databases that were interrogated. Missing information and differences in follow-up length may have influenced the comparative evaluation. The choice of including different centers has increased the total number of observations, introducing a center effect that cannot be thoroughly evaluated in the comparative study. The nonconsecutive nature of treatment choice in each center may have affected the selection bias typical of any nonrandomized trial.
Conclusion
Our study suggests that in a selected, propensity-matched population of patients with pararenal aneurysms, endovascular treatment and open repair may achieve similar early and midterm results, with comparable survival rates at 3 years. Higher rates of perioperative systemic complications may be expected after open repair, while fenestrated endografting is more prone to reintervention and visceral stenosis or occlusion. In centers experienced in endovascular and open aortic surgery, both treatment options should be offered to different patients, representing more complementary therapeutic solutions rather than a simplistic alternative in case of complex aneurysms.
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